Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So,…you know the entire point of the CTAP programme is to facilitate immediate ramp of viable product through BP partnership, networked through the FDA… right, Leo?
I’ve explained this how many times to you?
This is the fastest path to revenue.
Stop with this ‘we need to fund a p3’ BS. You don’t have the cash or the time.
CTAP, NOW.
...right. I feel like it's just boilerplate at this point in these filings.
LOTS of salary for no deliverables...
Weren't many of these from those KipsBay warrants we were wondering about when they might be exercised, 4mo ago or so?
Lol… IPIX is a mailbox with a website being run by a guy paying himself $600k/yr.
How can you compare this to the real businesses you listed?
Stop the madness and come back to earth.
The communication style and the 'build-out' have the operating style of a classic scam. Plain and simple. There's no PR agency prepped for deployment pending results. There's no legitimate consultant being used going in any direction. Zero staff. Zero acceptance of outside assistance. There's no trust in relationships outside of their little silo. I don't see this going anywhere. It's a lifestyle company, plain and simple.
Which is bananas because there's potential, pending favourable results.
No 'fantasy'. Just asking questions and thinking aloud.
You're the one that mentioned the 'timing' of all of this.
SEC lawyers look at all sorts of stuff.
It's not a matter of 'what I think'... it's what they can prove.
I'm not an attorney.
Not sure what's 'pretty disturbing' to you. This is the OTC and stuff like this happens not infrequently around here.
I haven't been poking about too much lately, but there's a ton of stuff that just doesn't add up, certainly. This timing-stuff being one of the more curious incidents.
Easily proven I believe, with a little Discovery, when presented in a court of law. Email time-stamps aren't difficult to acquire.
So connecting the dots... would this be tantamount to securities-fraud... pumping a stock, diluting (selling into volume based on the pumping PR's); knowing the trial hadn't met its primary endpoint?... all the while, paying yourself handsomely at shareholders expense, based on the sale of false-hope despite knowing it to be a lie?
Amen, and thank you.
Cogent and concise and sorely missed around here of late.
Hang in there. Your service and expertise are so greatly appreciated.
It's always possible to contract a scientific audit.
This was suggested to me by a friend who's a virologist who works at a BSL-3.
If you have access to lab-folk, a convo with them and a quote shouldn't be out of reach.
Relentlessly actually.
I have a million notes from convos over the years with The Accountant…
Charts, graphs, strategy etc.
followed with more notes and questions for him, and more calls/emails.
Nothing ever definitive from any of the interactions though, hence my irritation with the company.
He probably could’ve just left it at:
Do you understand the point of M&A's on the economics-side of things?
Perfectly summed up. THANK YOU.
Man... this board is so full of ridiculousness and finally someone else spouting some reality.
Fingers crossed for a miracle around here for sure.
But man, this has been a long and terrible nightmare for many.
Couldn't have a thing to do with further dilution, could it?
Too logical?
10 Feb 2021 OS -418,069,575
31 March 2021 OS- 426,673,198
1 Aug 2021 OS 445,612,278
Let's just say that there are folks close to him/this, who believe this to be the case.
That was the amount I was quoted for the tox work alone. Additionally, there's a reformulation needed, which would require another P1, so the overall expense is greater, but to complete the tox work first is a requirement.
That was a figure given to me from Leo a year or so ago when I enquired directly and was attempting to connect him with less toxic financing to advance things more rapidly.
I asked for an NDA at the time and wanted one for some PE interested parties, and he refused. I wonder why you wouldn't want more help to progress your drugs and clean up your financing?
I have some ideas now...
Progress... the world isn't waiting around for 'The Gold Standard' of Therapeutics apparently:
India’s DNA COVID vaccine is a world first – more are coming
https://www.nature.com/articles/d41586-021-02385-x?utm_source=Nature+Briefing&utm_campaign=bb922d89f0-briefing-dy-20210903&utm_medium=email&utm_term=0_c9dfd39373-bb922d89f0-46110006
The ZyCoV-D vaccine heralds a wave of DNA vaccines for various diseases that are undergoing clinical trials around the world.
Me 2 brother... me too.
And the OS.
Looks like Leo's been super busy diluting shareholders mercilessly yet again.
Jan 2020- OS 214M ~
30 Apr 2-2- OS 267,408,840
31 May 2020 OS- 296,688,311
30 June 2020 OS- 328,317,492
14 Sept 2020 OS- 343,579,992
16 nov 2020 OS- 355,957,332
30 Nov 2020 OS- 357,616,780
31 Dec 2020 OS- 367,984,689
31 Jan 2021 OS- 390,861,713
10 Feb 2021 OS -418,069,575
31 March 2021 OS- 426,673,198
01 Aug 2021 OS- 445,612,278
The theory goes that: this is what the ACTIV programme through the NIH is for. Whether The Accountant got his shit together and actually got involved with the effort is another story (I've asked and he's skirted the question).
-https://www.nih.gov/research-training/medical-research-initiatives/activ
-https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prioritized-testing-clinical-trials
Theoretically, the government is the partner and would assist with the lift to advance trials, develop and fast track structure, fund, facilitate manufacturing etc.
The DPA (Defense Production Act) could also be employed I believe, to fast track manufacturing as needed, and this could all be done and dusted and stockpiled in short order.
I guess we'll just have to see what happens.
(Notice that nowhere on the NIH page is IPIX/Brilacin mentioned... )
I'm in agreement that the bar is low. After re-reading many times, the topline breakdown... if B is even mildly functional, I have a hard time understanding how it could not be a step-up from SOC...BUT
Oh, you mean his little debt/equity swap that netted him 909,090 shares for a 'debt' of $100k? That one?
It's all well documented in SEC filings... no need to 'wonder if Mr Ehrlich did anything with his money'.
This doesn't raise any red flags?-
Utterly ridiculous.
It was a debt/equity swap and ultimately not completely dissimilar to what Enron was brought down for, in a nutshell. Way smaller scale.
Leo's using IPIX as an SPV essentially and doing nothing but selling equities to do quite literally nothing more than paying himself.
To date, there are no deals and no BP interest because trials have been inconclusive due to lack of statistically significant size. He knows this and yet has continued to run statistically insignificantly sized trials, all the while diluting the living shit out of shareholders and issuing pumping PR's to artificially inflate the share price so his toxic financing buddies can sell into the bump. It's grossly transparent if you've watched it over the course of time.
Additionally, he pays himself 5x what the industry norm is for a pre-revenue BioTech, and prioritizes paying himself over running trials (see: Kevetrin, B-OM, B-IBD).
Sure it's a 'sign of confidence'. He's confident the ordinary shareholder can't figure this out (it's the OTC after all) and since it's the OTC, it's the wild west and the SEC turns a blind eye to enforcement of matters such as this.
There's a special place in hell for people like this.
This is why I maintain that 'good science dies at the hands of bad management all the time'.
Leo is the cancer.
MAYBE B-Covid is the turnaround point, but I'm not holding my breath.
The point was that this is the OTC and nobody knows WTF is gonna happen here.
If past is prologue, then we fail and tank and fold.
But we have no idea. Not one iota.
This could be the hold of the century, on the flip-side. 1000%+ isn't unheard of for OTC equities and the sky could literally be the limit given the pieces in motion.
Personally, I'm planning on writing it all off, but will be pleasantly surprised if I can get back to even at the least. Time will tell.
Watch what happens on positive news if there's a partnership behind it...
I bought some trading shares back in 2020 based on the PR's, but have yet to unload anything.
It was against all better judgement.
I'm still waiting for some sort of 'delivery'.
I feel like this is the biggest dice-roll on earth. Sure the RBL findings are nice and all, but nothing in Vivo yet, and in the absence of any animal model data, we're flying in the dark.
Zero execution on any of these pie-in-the-sky PR's hyping 'blue sky market opportunities' for B-OM etc, so I guess we'll see what happens.
I'd like to get back to $1 (my basis) so I can bail, but not convinced we'll ever see that again, based on 'performance' to-date.
More like swindling shareholders out of more 'value' for the sake of him getting further ahead...
From a post by LR back in 2019:
Please provide evidence of the purchase of a single share by The Accountant... I'll wait.
The space is hot. Where the hell is The Accountant with the data?
September is here… tic toc…
Pfizer, Merck start late-stage trials for Covid-19 pills; Merck begins PhIII study on post-exposure treatment
https://endpts.com/covid-19-roundup-mesoblast-takes-another-hit-as-fda-demands-additional-trial-ahead-of-any-eua-review/
Now I wonder why he would do that, given that he:
- pays himself almost $1M/yr at shareholders expense (incl options etc)
- has gifted himself what, 18M shares with a par value of $0.00
- has no performance clauses attached to his remuneration, so gets paid regardless of what he does
So if the trial is great and there's an M&A / License etc, then great! He's the biggest winner!
...and if the trial bombs and the SP goes to zero, he's still paid himself around $7M over the course of 'running the company', so shareholders lose, but The Accountant wins again!
Why spend your own $ when you can use everyone else's?
Unlikely.
They have M&A teams, BizDev teams etc. This would be the job of Locust Walk et al, to organize, I'd like to think...
The last thing we want is The Accountant to 'negotiate' something resembling an M&A I think.
Note: The A.S. deal.
I think we could add BMS to this as well; having no SARS CoV-2 play currently, but funding to support one?
Hoping results from this current IPIX trial aren't 'suppressed' regardless of the outcome.
Interesting findings here related to research publication interference:
Health researchers report funder pressure to suppress results
Not disputing that.
I was mostly just looking at the alternative delivery method and what could be associated with it.
Totally agree it all rests on 'what happens next' with respect to how COVID is handled.
Hoping we don't get 'Ehrlich'd' yet again...
Many thanks for sharing these.